including projects with VIVUS, Inc., Hyperion, and Alexion
-- Achieved quality assurance milestone; audits of RAS unit conducted by
three global biopharmaceutical companies.
-- Expanded the RAS team in response to global demand for the group's
services; team now totals 10 professionals.
-- Achieved continued strong revenue growth; RAS revenue grew 36%
sequentially compared with the prior quarter.
-- Successfully re-listed on the Nasdaq Capital Market and began trading
on November 27, 2007.
-- Continued to make progress with FDA Cooperative Research and
Development Agreement (CRADA) with the successful installation of PKS
into the Agency's IT environment.
Additional Financial Results
Gross margin in the third quarter of fiscal 2008 was 64%. GAAP net income attributable to common stockholders was $532,000 in the fiscal third quarter of 2008, up 77% compared with $300,000 in the comparable period of fiscal 2007. Net earnings per basic and diluted share were $0.06 and $0.05 respectively during the third quarter of fiscal 2008 compared with $0.05 and $0.04 respectively during the third fiscal quarter of 2007. Non-GAAP net earnings per basic and diluted share for the third quarter of fiscal 2008, which exclude the impact of stock-based compensation, were both $0.09 compared with $0.08 and $0.07 respectively for the third quarter of fiscal 2007. Historical earnings per share calculations for the quarter and nine-month periods have been updated to reflect the 1-for-3 reverse stock split effected in November 2007.
Revenue for the first nine months of fiscal 2008 was $20.8 million, up
16% from $17.8 million reported for the same period of fiscal 2007. Gross
margin for the first nine months of fiscal 2008 was 65%. GAAP net income
for the first nine months of fiscal 2008 was $1.1 million up 9% compared
|SOURCE Pharsight Corporation|
Copyright©2008 PR Newswire.
All rights reserved